From the Journals

Adding vasopressin in distributive shock may cut AF risk


 

FROM JAMA


The current Surviving Sepsis guidelines suggest either adding vasopressin to norepinephrine to help raise mean arterial pressure to target or adding vasopressin to decrease the dosage of norepinephrine. Those are considered weak recommendations based on moderate quality of evidence, Dr. McIntyre and colleagues noted in their report.

Authors of the study reported disclosures related to Tenax Therapeutics, Orion Pharma, Ferring Pharmaceuticals, GlaxoSmithKline, and Bristol-Myers Squibb, among other entities.

SOURCE: McIntyre WF et al. JAMA. 2018;319(18):1889-900.

Pages

Recommended Reading

Beware of polypharmacy in patients taking warfarin
MDedge Cardiology
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Cardiology
Takotsubo cardiomyopathy incidence, mortality on the rise
MDedge Cardiology
Permanent His-bundle pacing superior to RV pacing
MDedge Cardiology
MDedge Daily News: Time to let more pregnant women into drug trials?
MDedge Cardiology
Apixaban prevails in study of 163,000 DOAC users
MDedge Cardiology
VIDEO: Screening ECG patch boosts AF diagnoses ninefold
MDedge Cardiology
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Cardiology
Women’s representation in CV drug trials still lagging
MDedge Cardiology
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Cardiology